Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8221 results

  1. Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy [TSID12173]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Nifedipine - Lidocaine for Chronic Anal Fissure [TSID 12093]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    In development Reference number: GID-TA11497 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    Awaiting development Reference number: GID-TA11858 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    Awaiting development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development Reference number: GID-TA11140 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    In development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    In development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    In development